



NDA 21-223/S-009 & S-010

Novartis Pharmaceuticals Corporation  
Attention: Annmarie Petraglia  
Senior Associate Director, Drug Regulatory Affairs  
One Health Plaza  
East Hanover, NJ 07936-1080

Dear Ms. Petraglia:

Please refer to your supplemental new drug applications dated September 24, 2004, received September 27, 2004 (NDA 21-223/S-009) and November 22, 2004, received November 23, 2004 (NDA 21-223/S-010), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Zometa (zoledronic acid) Injection.

These "Changes Being Effected" supplemental new drug applications provide for a new subsection entitled **Osteonecrosis of the Jaw** in the **Precautions** section of the package insert, and updated information in the **Renal Insufficiency** subsection of the **Precautions** section, the **Adverse Reaction** subsection of the **Warnings** section, and the **DOSAGE AND ADMINISTRATION** section concerning dosing with pre-existing renal insufficiency.

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the final printed labeling (FPL) submitted on November 22, 2004.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Randy Hedin, R.Ph., Senior Regulatory Management Officer, at (301) 827-6392.

Sincerely,

*{See appended electronic signature page}*

David G. Orloff, M.D.  
Director  
Division of Metabolic and Endocrine Drug Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

Enclosure

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
David Orloff

1/31/05 02:58:28 PM